Cytokinetics, Inc. (CYTK) Reports In-Line Q2 Loss of 13c/Share
Cytokinetics, In
c. (NASDAQ: CYTK) reported Q2 EPS of ($0.13), in-line with the analyst estimate of ($0.13).
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
c. (NASDAQ: CYTK) reported Q2 EPS of ($0.13), in-line with the analyst estimate of ($0.13).For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.